PRTC vs. OXB, BVXP, ONT, HVO, AVCT, GNS, UPR, AMS, CRW, and BMK
Should you be buying PureTech Health stock or one of its competitors? The main competitors of PureTech Health include Oxford Biomedica (OXB), Bioventix (BVXP), Oxford Nanopore Technologies (ONT), hVIVO (HVO), Avacta Group (AVCT), Genus (GNS), Uniphar (UPR), Advanced Medical Solutions Group (AMS), Craneware (CRW), and Benchmark (BMK). These companies are all part of the "medical" sector.
PureTech Health (LON:PRTC) and Oxford Biomedica (LON:OXB) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their community ranking, dividends, earnings, media sentiment, analyst recommendations, institutional ownership, profitability, valuation and risk.
Oxford Biomedica has higher revenue and earnings than PureTech Health. PureTech Health is trading at a lower price-to-earnings ratio than Oxford Biomedica, indicating that it is currently the more affordable of the two stocks.
PureTech Health received 171 more outperform votes than Oxford Biomedica when rated by MarketBeat users. Likewise, 86.58% of users gave PureTech Health an outperform vote while only 66.79% of users gave Oxford Biomedica an outperform vote.
Oxford Biomedica has a consensus target price of GBX 498.75, suggesting a potential upside of 52.76%. Given Oxford Biomedica's higher possible upside, analysts plainly believe Oxford Biomedica is more favorable than PureTech Health.
In the previous week, PureTech Health's average media sentiment score of 0.00 equaled Oxford Biomedica'saverage media sentiment score.
PureTech Health has a beta of 0.93, indicating that its stock price is 7% less volatile than the S&P 500. Comparatively, Oxford Biomedica has a beta of 1.03, indicating that its stock price is 3% more volatile than the S&P 500.
PureTech Health has a net margin of 0.00% compared to Oxford Biomedica's net margin of -51.78%. PureTech Health's return on equity of -13.25% beat Oxford Biomedica's return on equity.
80.0% of PureTech Health shares are held by institutional investors. Comparatively, 58.1% of Oxford Biomedica shares are held by institutional investors. 14.6% of PureTech Health shares are held by insiders. Comparatively, 16.2% of Oxford Biomedica shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
Summary
Oxford Biomedica beats PureTech Health on 8 of the 15 factors compared between the two stocks.
Get PureTech Health News Delivered to You Automatically
Sign up to receive the latest news and ratings for PRTC and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding PRTC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
PureTech Health Competitors List
Related Companies and Tools
